home.social

#therapeutics — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #therapeutics, aggregated by home.social.

  1. Exosomes containing signaling molecules derived from wild Scandinavian flatworms can significantly accelerate tissue repair and wound healing in human skin models.
    #ChemicalBiology #RegenerativeMedicine #MolecularBiology #Therapeutics #sflorg
    sflorg.com/2026/04/bio04282601

  2. Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

    Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to…
    #NewsBeep #News #Health #AU #Australia #Bases #BreastCancer #Cancer #carcinoma #Cell #cellbiology #Gene #GeneExpression #Genes #Genomic #medicine #Metastasis #Proliferation #protein #research #StemCells #Therapeutics #therapy
    newsbeep.com/au/602035/

  3. Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

    Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to…
    #NewsBeep #News #Health #AU #Australia #Bases #BreastCancer #Cancer #carcinoma #Cell #cellbiology #Gene #GeneExpression #Genes #Genomic #medicine #Metastasis #Proliferation #protein #research #StemCells #Therapeutics #therapy
    newsbeep.com/au/602035/

  4. Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment

    Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment February 25, 2026 | Wednesday | News Company is eligible to receive a $40 million milestone payment upon first commercial sale in Ja…
    #Japan #JP #JapanNews #DMD #genetherapy #launch #news #Therapeutics
    alojapan.com/1457342/sarepta-t

  5. Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment

    Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment February 25, 2026 | Wednesday | News Company is eligible to receive a $40 million milestone payment upon first commercial sale in Ja…
    #Japan #JP #JapanNews #DMD #genetherapy #launch #news #Therapeutics
    alojapan.com/1457342/sarepta-t

  6. alojapan.com/1457342/sarepta-t Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment #DMD #GeneTherapy #Japan #JapanNews #launch #news #Therapeutics Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment February 25, 2026 | Wednesday | News Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan US-based Sarepta Therapeutics, Inc. has announced the commercial launc

  7. alojapan.com/1457342/sarepta-t Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment #DMD #GeneTherapy #Japan #JapanNews #launch #news #Therapeutics Sarepta Therapeutics announces commercial launch of ELEVIDYS in Japan for DMD treatment February 25, 2026 | Wednesday | News Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan US-based Sarepta Therapeutics, Inc. has announced the commercial launc

  8. When the immune system detects a protein from a pathogen,
    it’s supposed to dispatch killer T cells to eliminate the invader.

    Some cancers can interfere with this process by hijacking the checkpoint proteins that keep our immune system from revving out of control
    and using them to turn T cells off.

    Starting in the mid-1990s, several research teams found success by treating mice with #checkpoint #inhibitors,
    -- then a new class of drugs designed to keep tumor cells from concealing their identity and signaling, effectively, “nothing to see here.”

    Thirty years on, checkpoint inhibitors have become a transformative tool in cancer treatment, especially for melanoma.

    The research that went into developing checkpoint inhibitors showed conclusively that immune cells detect cancer much in the same way they identify other pathogens:

    through differences in protein structure determined by DNA
    —a crucial insight.

    But as revolutionary as checkpoint inhibitors have been for immunotherapy, they don’t work for everyone
    —far from it.

    Some 80 percent of patients do not respond to this class of drugs.

    Researchers are still trying to understand all the mechanisms that play a role in determining who does respond,
    but one key factor is whether the immune system is able to recognize tumor cells on the basis of their mutations.

    This is where mRNA vaccines come in.

    #Jason #Luke, a melanoma researcher who now serves as chief medical officer of mRNA-medicine start-up #Strand #Therapeutics,
    helped to design several ongoing clinical trials of mRNA vaccines for cancer.

    He explains that both checkpoint inhibitors and mRNA vaccines build on our deep evolutionary adaptation for fighting pathogens
    by identifying the proteins they shed in our bodies.

    But checkpoint inhibitors are effective only if the patient’s immune system recognizes the cancer as a threat.

    In contrast, mRNA vaccines have the potential to work even in patients whose cancers haven’t spurred much immune response.

    The trick, Luke says, is using computational tools to decipher which of a given tumor’s mutations are most likely to be found by the immune system.

    #MichaelMemoli
    #WilliamColey #immunotherapy #stroma #MHC

  9. Redefining control in anaerobic microbiome workflows

    In this interview, Sheela Muley, Product Manager at Molecular Devices, and Dr Sushmita Sudarshan, Application Scientist in Assay Development at Molecular Devices…
    #NewsBeep #News #Technology #Assay #AU #Australia #Automation #Contamination #Genes #Genome #Genomic #heat #Imaging #ImmuneSystem #Lifescience #LiquidHandling #Metabolism #Microbiome #morphology #oxygen #Phenotype #research #Software #Therapeutics
    newsbeep.com/au/264350/

  10. EthanRusso.org is the personal website of #EthanRusso, MD, a #neurologist and medical #researcher.

    I’m proud to announce a new course offering with our partners at MM411, “Certificate of Advanced #Cannabis #Pharmacology & #Therapeutics”. This course is for practitioners and professionals who want to provide evidence-based care and support to patients seeking alternatives to conventional pharmaceutical therapies.

    #WEEDMoB #Hanfgeschichten #Streeck #NinaWarken #Hanf

    youtube.com/channel/UC2RH7gOz0

  11. EthanRusso.org is the personal website of #EthanRusso, MD, a #neurologist and medical #researcher.

    I’m proud to announce a new course offering with our partners at MM411, “Certificate of Advanced #Cannabis #Pharmacology & #Therapeutics”. This course is for practitioners and professionals who want to provide evidence-based care and support to patients seeking alternatives to conventional pharmaceutical therapies.

    #WEEDMoB #Hanfgeschichten #Streeck #NinaWarken #Hanf

    youtube.com/channel/UC2RH7gOz0

  12. EthanRusso.org is the personal website of #EthanRusso, MD, a #neurologist and medical #researcher.

    I’m proud to announce a new course offering with our partners at MM411, “Certificate of Advanced #Cannabis #Pharmacology & #Therapeutics”. This course is for practitioners and professionals who want to provide evidence-based care and support to patients seeking alternatives to conventional pharmaceutical therapies.

    #WEEDMoB #Hanfgeschichten #Streeck #NinaWarken #Hanf

    youtube.com/channel/UC2RH7gOz0

  13. EthanRusso.org is the personal website of #EthanRusso, MD, a #neurologist and medical #researcher.

    I’m proud to announce a new course offering with our partners at MM411, “Certificate of Advanced #Cannabis #Pharmacology & #Therapeutics”. This course is for practitioners and professionals who want to provide evidence-based care and support to patients seeking alternatives to conventional pharmaceutical therapies.

    #WEEDMoB #Hanfgeschichten #Streeck #NinaWarken #Hanf

    youtube.com/channel/UC2RH7gOz0

  14. EthanRusso.org is the personal website of #EthanRusso, MD, a #neurologist and medical #researcher.

    I’m proud to announce a new course offering with our partners at MM411, “Certificate of Advanced #Cannabis #Pharmacology & #Therapeutics”. This course is for practitioners and professionals who want to provide evidence-based care and support to patients seeking alternatives to conventional pharmaceutical therapies.

    #WEEDMoB #Hanfgeschichten #Streeck #NinaWarken #Hanf

    youtube.com/channel/UC2RH7gOz0